Abel Hall LLC
AKBA icon

Abel Hall LLC’s Akebia Therapeutics AKBA Stock Holding History

Abel Hall LLC’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-75,438
Closed -$86K – 899
2026
Q2 		$86K Buy
+75,438
New +$89.8K 0.01% 854
2025
Q4 		– Sell
-10,500
Closed -$28.7K – 715
2025
Q3 		$28.7K Sell
10,500
-118
-1% -$393 0.01% 310
2025
Q2 		$38.6K Buy
+10,618
New +$29.2K 0.02% 261

Other funds holding AKBA

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Choreo LLC
Choreo LLC Rockford, Illinois $9.7B AUM 18.43% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
PFG Private Wealth Management
PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Traynor Capital Management
Traynor Capital Management Malvern, Pennsylvania $2.17B AUM 49.16% 1-Year Est. Return

Abel Hall LLC's AKBA Position: Q3 2026 in Review

Abel Hall LLC sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 75,438 shares — an estimated $86K sold.

Abel Hall LLC first reported a position in AKBA in Q2 2025 and held it in 3 quarters. The position peaked at $86K in Q2 2026. 35 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Abel Hall LLC reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Abel Hall LLC sold 75,438 Akebia Therapeutics shares in Q3 2026, an estimated $86K.
  • Abel Hall LLC first reported a position in Akebia Therapeutics in Q2 2025 and held it in 3 quarters.
  • Abel Hall LLC's Akebia Therapeutics position peaked at $86K in Q2 2026.
  • 35 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.